Brimonidine Tartrate

7 trials 4 recruiting SOphthalmology & ENT

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

4 Recruiting

2 Completed trials

4 Sponsors

14 Countries

Phase III

Phase II

Phase I (FiH)

Phase III: 1 Phase II: 5 Phase I (FiH): 1

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

Indications tested

Cervix carcinoma 1 Myopia 1 Malignant peritoneal neoplasm 1 Fallopian tube cancer 1 Endometrial cancer recurrent 1 Ovarian epithelial cancer 1

Sponsors using this IMP

Tarian Pharma 3 AbbVie Deutschland GmbH & Co. KG 2 Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal 1 Seagen Inc. 1

All trials

7 total

TAR-0520 gel in Hand and Foot Syndrome Pending

2025-524008-32-00 Phase II 1 country Tarian Pharma
First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Recruiting

2023-506842-22-00 Phase I (FiH) 7 countries AbbVie Deutschland GmbH & Co. KG
TAR-0520 gel in EGFR inhibitor-induced folliculitis Recruiting

2024-516339-28-00 Phase II 1 country Tarian Pharma
Brimonidine eye drops in the prevention of myopia progression Recruiting

2025-521878-33-00 Phase II 1 country Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Caj…
TAR-0520 Gel in taxanes-induced peripheral neuropathy Recruiting

2025-521674-33-00 Phase II 1 country Tarian Pharma
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec… Ended

2023-505617-24-00 Phase II 4 countries AbbVie Deutschland GmbH & Co. KG
A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended

2023-503813-31-01 Phase III 13 countries Seagen Inc.

Showing 1–7 of 7 trials

← All drugs A–Z